​A New Milestone for 露美瑞 Lumirix® in Taiwan

A New Milestone for 露美瑞 Lumirix® in Taiwan

We're pleased to share that 露美瑞乳膏 Lumirix® (Ruxolitinib) Cream 15mg/g has received official approval in Taiwan. 

Lumirix® is indicated for the treatment of non-segmental vitiligo with facial involvement from 12 years of age. This approval is an important milestone in our commitment to providing effective treatment options for patients living with vitiligo, and a step in the process toward making Lumirix® accessible to patients in Taiwan.

IMPORTANT NOTICE: Lumirix® is a prescription medicine. This post is for informational purposes only and does not constitute medical advice or promotion. Please refer to the full Prescribing Information.